MCC950 → Peripheral Neuropathy

Original Indication

NLRP3 Inflammasome Inhibitor (Research Compound for Inflammatory Diseases)

Proposed New Indication

MCC950, a potent and selective small-molecule inhibitor of the NLRP3 inflammasome, shows preclinical promise in alleviating chronic pain and promoting nerve repair by suppressing pyroptosis in peripheral neuropathy.

Proposed Mechanism

Targets: NLRP3_Inflammasome

Inhibition of NLRP3 inflammasome, leading to reduced pyroptosis, inflammation, and pain in the context of peripheral neuropathy.

Evidence

Level: Preclinical (systematic review summarizing in vivo/in vitro studies for NLRP3 inhibitors in PN)

Source: Wei, J., et al. (2026). Pyroptosis in Peripheral Neuropathy: From Molecular Mechanisms to Therapeutic Targeting. CNS Neuroscience & Therapeutics, 32(1), e70760.

Reference: PubMed 41574659

Repurposing Score